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Ischemic preconditioning and the
risk of acute kidney injury
To the Editor: We have read with interest the paper by
Zimmerman et al.,1 in which the authors randomized to
either ischemic preconditioning or no intervention 120
patients undergoing cardiac surgery. The authors reported a
marked 57% lower risk for acute kidney injury (AKI) in
patients in whom preconditioning occurred.
Such a result may be partly explained by the study being
underpowered. The authors reported that a total of 120
subjects would provide 62% power to detect a 50% reduction
in the risk of AKI. The main concern with underpowered
studies is the increased risk of type II error (failing to reject a
false null hypothesis). However, an often underlooked pro-
blem arising from underpowered studies is the increased risk
of type I error (failing to reject a true null hypothesis).2 In
particular, simulation studies have shown how studies with
low power tend to yield incorrectly inﬂated effect size estimates.3
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The Authors Reply: We appreciate the opportunity to
address concerns regarding statistical power in our study.1
Ferraro and Gambaro’s2 statement that underpowered studies
are at increased risk for type I error is, in our opinion, an
oversimpliﬁcation of a rather complex issue. It can be argued
that equal P-values represent equal risks for type I error
regardless of sample size, or even that lower statistical power
strengthens the evidence represented by a given P-value and
reduces the likelihood of type I error.3 As we found an effect
of remote ischemic preconditioning that was highly statisti-
cally signiﬁcant (P¼ 0.004), we consider it improbable that
ours was a ‘false-positive’ study.
The authors raise the valid point that because small,
underpowered studies require more extreme results to reach
statistical signiﬁcance, they tend to overestimate effect size.
We regret not acknowledging this issue in our discussion of
limitations. Our a priori power analysis was based on pilot
data. If the observed data in our study are ‘true’, then the
power to detect the observed differences is substantially higher
than the 62% estimated before the study started, and is rather
83%. At 60% power, the simulation studies reported by
La Caze, et al.4 indicate that the probability of signiﬁcant result
bias is quite low, and at 80% power ‘shrinks to negligible
levels’. We therefore consider it unlikely that our ﬁndings are
seriously biased vis-a`-vis the effects of low statistical power.
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Biomarker for interstitial
inflammation
To the Editor: Zhang et al.1 have conducted a proof-of-
concept cross-sectional study on biomarkers of interstitial
inﬂammation in lupus nephritis. Although the authors allude
to biomarkers leading to a ‘continuous readout of kidney
pathology’, they use a dichotomous gold standard (none–mild
vs. moderate–severe interstitial inﬂammation on histology). It
would be more informative to observe the four groups
separately as classiﬁed by the blinded nephropathologist. Was
there a gradient (dose–response) in the levels of biomarkers in
the four groups of none, mild, moderate, and severe? This
may not be ‘clinically signiﬁcant’ but will increase conﬁdence
in the result.
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